Isatuximab plus pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma: Appraisal consultation document

DRAFT guidance does not recommend use of this regimen intended for adults who have had at least 2 treatments (including lenalidomide and a proteasome inhibitor) and whose disease has progressed on the last treatment, as it was not considered a cost-effective use of NHS resources.


National Institute for Health and Care Excellence